reason report
deal pois close pbm sell season robust pt
bottom line publish updat model
follow result encourag deal aet mp
appear readi close near-term believ
posit catalyst stock also like pbm sell season
seem progress well better expect also
like seem re-focus retail streamlin effort
hope result net save new model
stand-alon entiti believ use show
core earn without aet would includ op
book busi maintain op increas
pt
worri new york state approv
receiv sever question investor regard state
approv process deal accord medacorp specialist
check state plan tri block deal
would form coalit alreadi effort like would
coordin doj medacorp specialist
spoken indic us coalit
form one state taken lead role
tri block transact theori state abil
tri block deal judiciari system medacorp
specialist spoken indic us
rare possibl view state new york
work certain issu relat new york possibl
state want wait mid-term elect provid
approv
pbm assumpt seem conserv posit
surpris post net new win pbm
like retent rate fact
renew complet model pbm y/i revenu
growth seem reason us given
net new win well growth core inflat
model pbm revenu growth also seem reason
us given fact worth annual revenu
esrx mp assum oper margin leverag
pbm difficult comp health
insur fee medacorp specialist check usual indic plan
like retail channel model pharmacist ensur
prescript actual pick use also
encourag expect synergi
follow deal
net debt total capit
compani inform leerink partner llc research
revenu billion
adjust ep exclud acquisit amort one-tim item exclud interest expens relat aet transact exclud
revenu earn aet deal
pleas refer page import disclosur price chart analyst certif
retail volum make come-back y/i growth
adjust rx retail in-lin guidanc still
view near volum growth excel adjust
rx basic flat manag appropri enter
manag care deal especi part effort grow traffic
volum store effort seem work
well disappoint former cfo dave denton took larg
piec tax save decid re-invest back
retail busi caus y/i declin retail oper
incom encourag new cfo boratto highlight
still expect gross benefit enterpris streamlin
effort save expect ramp
model retail adjust oper incom growth y/i
y/i respect despit fact streamlin
acceler deal like drive higher volum
store
excel quarter model updat ep
respect unchang introduc
ep pt seem reason base stock
trade still well averag
ntm pe remain posit close deal
signific near-term posit catalyst
believ stand benefit brand gener convers pbm share gain growth
retail high growth rate specialti pharmaceut retail pharmaci
pbm believ differenti offer substanti buy power allow
compani price highli competit deliv high qualiti care uniqu cost
save model mani plan sponsor seek narrow network consid one
best market -- preval expect increas next
year estim alreadi one largest retail chain countri expect
addit growth come open new pharmaci acquisit
independ pharmaci smaller chain next sever year expect gener
drug launch advent biosimilar remain industri trend help drive
margin expans believ minuteclin benefit grow emphasi
popul health manag expect see increment benefit sell
season express script esrx optum continu streamlin oper
integr new custom win acquisit also posit propos cvs/aet
combin deal enabl live integr medic pharmaci
benefit aet live creat new sourc revenu earn
next month expect share trade ep
would put stock price target believ deserv
trade slight discount histor multipl given slowdown gener launch calendar
on-going challeng environ restrict narrow network howev
pick gross win pbm sell season reflect strength
core busi model furthermor lap lost rx headwind retail top-
line growth re-acceler believ well posit take advantag growth
gener specialti pharmaceut believ retail pbm valu proposit
mainten choic offer reson well market believ
continu win pbm share also help drive volum retail store
competit high chang retail pharmaci pbm market highli
competit industri consolid chang retail pbm landscap
acquisit medco express script merger health solut catalyst
health solut walgreen allianc boot combin
consolid market share among largest compani pbm may need price
aggress retain custom impact profit custom retent
macroeconom climat uncertain continu econom slowdown would bode
poorli client individu consum retail pharmaci product pbm plan
sponsor would suffer averag unemploy rate along averag level
consum spend purchas power would decreas prescript drug util weak
macroeconom outlook would also hurt profit pbm client possibl decreas
number cover live
organ govern entiti third-parti seek decreas prescript
drug cost seek increas substitut gener drug brand drug
normal benefici bottom line retail pharmaci downward pressur
reimburs rate pharmaci could start cut away margin consolid among
gener pharmaceut manufactur may squeez pharmaci would difficult
negoti reduc acquisit cost strong focu feder state govern
rein healthcar cost healthcar financ reimburs rate subject chang
variou polit econom interest exert influenc regulatori environ
failur retain/win new pbm contact pbm contract provid healthcar servic plan
member typic durat three year mean pbm client base
renew given year inher risk exist abil retain contract
renew also certain pbm client may tailor contract deviat typic term
may renegoti contract prior expir
medicar part regul risk particip medicar part prescript
drug program retail pharmaci realiz increas drug util compress
margin individu migrat higher margin plan one howev medicar
part busi could impact one sever factor includ chang drug cost
retire drug subsidi revis medicar program requir reduct fund failur
integr acquir medicar part busi failur win new contract
transact risk risk cvs/aet transact either wont close due
regulatori constraint integr deal may prove challeng
expect also risk invest commun sentiment transact
combin segment revenu
incom statement model fiscal year end decemb mm
pharmaci retail
good sold
revenu
revenu
earn alloc particip secur
net loss attribut non-control interest
adjust incom continu oper
incom statement model fiscal year end decemb mm
adjust one-tim item
adj incom cont op ex amort
adjust dilut ep ex amort
net incom continu oper
net loss attribut non-control interest
prefer dividend net incom tax benefit
net incom attibut caremark
cog net revenu
oper expens net revenu
depreci amort
 total
incom statement model fiscal year end decemb mm
cog net revenu
oper expens net revenu
depreci amort
pharmaci total revenu
third parti pharmaci revenu
depreci amort
combin revenu
depreci amort
